As KIR and KIR ligand genotypes affect the immune response, and seem to influence the response to RA treatment using anti-TNF-α agents [13], we wondered whether these genotypes might also influence the outcome of MTX therapy of RA. Here, KIR3DL1 is linked to rheumatoid arthritis.